Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).
Overweight or obese women with gestational diabetes mellitus (GDM) may fare well with metformin treatment, which is reported in a recent study to safely and effectively prevent excessive and promote adequate gestational weight gain (GWG) independent of age, body mass index (BMI) and timing of GDM diagnosis, among others.
Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.
Gestational diabetes and abnormal glucose levels in pregnancy, as determined with an oral glucose challenge test (OGCT) at 24–28 weeks gestation, could signal a future risk of cardiovascular disease (CVD)*, according to a recent study.
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Eating vegetable and protein before carbohydrate attenuated postprandial glucose response in healthy Asian adults, according to the PATTERN* study, suggesting that behavioural change in eating sequence may be a potential strategy for modulating glycaemic response.
The cardiovascular (CV) benefits of the SGLT2* inhibitor dapagliflozin extend across a broad spectrum of patients with type 2 diabetes (T2D) and high CV risk, in particular those with heart failure with reduced ejection fraction (HFrEF), reports a subanalysis of the DECLARE-TIMI 58 trial presented at ACC.19 Annual Scientific Session.
The risk of cardiovascular (CV) disease (CVD) is significantly higher among patients with rheumatoid arthritis (RA) than those with type 2 diabetes (T2D), results of the CARRÉ* study reveal. Such risk persisted even after adjusting for traditional CV risk factors, which suggests that systemic inflammation is an independent contributor to CV risk.
A recent retrospective study from Singapore identified several factors associated with a higher risk of mortality following hip fracture, including male sex, older age, and a higher number of comorbidities.
Walking downhill within 1 hour after meals may help reduce bone resorption in postmenopausal women with diabetes, according to new research. Walking uphill does not provide the same osteogenic response.